Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas
NCT03187210 · Insel Gruppe AG, University Hospital Bern · PHASE1/PHASE2 · suspended · last registry update 2025-03-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “low accrual” | – | Registry record, Insel Gruppe AG, University Hospital Bern |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-12Phase 3 first posted: Children's Oncology Group, Cyclophosphamide + Dactinomycin (NCT07466316)
- 2026-03-06Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab vedotin (NCT05171647)
- 2026-02-25Results posted on the registry: ECOG-ACRIN Cancer Research Group, Venetoclax + Vincristine Liposomal (NCT03504644)
- 2026-02-19Phase 3 first posted: Merck Sharp & Dohme LLC, Sacituzumab tirumotecan + Vinflunine (NCT07419295)
- 2026-02-04Results posted on the registry: AstraZeneca, Dato-DXd + Capecitabine (NCT05104866)
- 2026-01-29Results posted on the registry: University of Wisconsin, Madison, Rituximab + Cyclophosphamide (NCT03943901)
- 2026-01-16Phase 3 first posted: Guliz Ozgun, enfortumab vedotin and pembrolizumab (EV/P) (NCT07346053)
- 2026-01-08Results posted on the registry: ECOG-ACRIN Cancer Research Group, Abiraterone Acetate + Androgen deprivation therapy (NCT03419234)
- 2025-12-18Phase 3 first posted: Nationwide Children's Hospital, Bridging Chemotherapy + Induction Cycles A1-A3 (NCT07291102)
- 2025-10-23Phase 3 first posted: SWOG Cancer Research Network, Cyclophosphamide + Doxorubicin Hydrochloride (NCT07220187)
- 2025-10-20Phase 3 first posted: Eli Lilly and Company, Vepugratinib + EV (NCT07218380)
- 2025-10-20Phase 3 first posted: AstraZeneca, AZD5335 + Mirvetuximab Soravtansine (MIRV) (NCT07218809)
- 2025-10-10Phase 3 first posted: AstraZeneca, AZD0486 + R-mini-CHOP (NCT07215585)
- 2025-10-09Phase 3 first posted: Eli Lilly and Company, Sofetabart Mipitecan + Paclitaxel (NCT07213804)
- 2025-10-09Phase 3 first posted: Amgen, Xaluritamig + Abiraterone acetate (NCT07213674)
- 2025-09-22Results posted on the registry: St. Jude Children's Research Hospital, Venetoclax + Navitoclax (NCT05192889)
- 2025-09-15Phase 3 first posted: BioNTech SE, Pumitamig + Nab-paclitaxel/Paclitaxel (NCT07173751)
- 2025-08-19Phase 3 first posted: Daiichi Sankyo, Dato-DXd + Carboplatin (NCT07129993)
- 2025-08-11Results posted on the registry: European Organisation for Research and Treatment of Cancer - EORTC, Brentuximab Vedotin + Adriamycin (NCT03517137)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Lenalidomide + Rituximab (NCT02911142)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
- 2025-07-20Results posted on the registry: Eli Lilly and Company, Ramucirumab + Cyclophosphamide (NCT04145349)
- 2025-07-18Phase 3 first posted: Children's Oncology Group, Bortezomib + Calaspargase Pegol (NCT07072585)
- 2025-06-12Results posted on the registry: National Cancer Institute (NCI), Brentuximab Vedotin + Dacarbazine (NCT03907488)
- 2025-05-30Results posted on the registry: St. Jude Children's Research Hospital, COPAD + COP, COPD M3, CYM (NCT01046825)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision